<?xml version="1.0" encoding="UTF-8"?>
<ref id="B59-pharmaceuticals-13-00096">
 <label>59.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ranieri</surname>
    <given-names>V.M.</given-names>
   </name>
   <name>
    <surname>Pettilä</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Karvonen</surname>
    <given-names>M.K.</given-names>
   </name>
   <name>
    <surname>Jalkanen</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Nightingale</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Brealey</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Mancebo</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Ferrer</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Mercat</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Patroniti</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Effect of intravenous interferon β-1a on death and days free from mechanical ventilation among patients with moderate to severe acute respiratory distress syndrome</article-title>
  <source>JAMA</source>
  <year>2020</year>
  <volume>323</volume>
  <fpage>725</fpage>
  <pub-id pub-id-type="doi">10.1001/jama.2019.22525</pub-id>
 </element-citation>
</ref>
